Brazil Expands Access to New Medical Technologies

Brazil Expands Access to New Medical TechnologiesEffective February 17, 2025, Brazil’s National Supplementary Health Agency(ANS) approved incorporating new technologies into the list of health procedures and events, expanding access to exams, devices, and treatments. According to the ANS, the list of procedures already includes more than 3,000 health technologies that are compulsorily covered by regulated health plans.

The following tests, procedures, and medicines are now included in the ANS list:

  1. Multiplex PCR tests – It will now be possible to conduct tests to detect multiple bacterial, viral, and fungal agents that cause meningitis and encephalitis, facilitating more accurate and rapid diagnosis.
  2. Left Ventricular Assist Device (LVAD) – Indicated for patients with advanced left ventricular heart failure, the continuousøow, centrifugal LVAD offers a therapeutic option for those who are not eligible for heart transplantation, significantly improving quality of life.
  3. Romiplostim – A medication indicated for adults with primary idiopathic thrombocytopenic purpura, a condition that reduces platelets in the blood and can cause bleeding. It is an option for patients who do not respond well to or depend on continuous use of corticosteroids. The update to the Utilization Guideline(UGD) 158 now includes Romiplostimas, an outpatient injectable drug therapy.

If you need support with your benefits in Brazil, please contact Asinta, and we will put you in touch with SCIATH’s local experts.